Exact Mass: 451.36950980000006

Exact Mass Matches: 451.36950980000006

Found 119 metabolites which its exact mass value is equals to given mass value 451.36950980000006, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Olivoretin D

(4S,7S,10S,13R)-13-Ethenyl-1,3,4,5,7,8,10,11,12,13-decahydro-4-(hydroxymethyl)-8,10,13-trimethyl-7,10-diisopropyl-6H-benzo[g][1,4]diazonino[7,6,5-cd]indol-6-one

C28H41N3O2 (451.3198606)


D009676 - Noxae > D011042 - Poisons > D008235 - Lyngbya Toxins D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins D009676 - Noxae > D002273 - Carcinogens D009676 - Noxae > D007509 - Irritants

   

(11Z,14Z)-Eicosadienoylcarnitine

3-[(11Z,14Z)-Icosa-11,14-dienoyloxy]-4-(trimethylammonio)butanoic acid

C27H49NO4 (451.36613940000007)


(11Z,14Z)-Eicosadienoylcarnitine is an acylcarnitine. More specifically, it is an (11Z,14Z)-icosa-11,14-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (11Z,14Z)-Eicosadienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (11Z,14Z)-Eicosadienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(8Z,11Z)-Icosa-8,11-dienoylcarnitine

3-(icosa-8,11-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C27H49NO4 (451.36613940000007)


(8Z,11Z)-icosa-8,11-dienoylcarnitine is an acylcarnitine. More specifically, it is an (8Z,11Z)-icosa-8,11-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (8Z,11Z)-icosa-8,11-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (8Z,11Z)-icosa-8,11-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

11-(3-Methyl-5-propylfuran-2-yl)undecanoylcarnitine

3-{[11-(3-methyl-5-propylfuran-2-yl)undecanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C26H45NO5 (451.32975600000003)


11-(3-methyl-5-propylfuran-2-yl)undecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-(3-methyl-5-propylfuran-2-yl)undecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-(3-methyl-5-propylfuran-2-yl)undecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 11-(3-methyl-5-propylfuran-2-yl)undecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

10-(3,4-Dimethyl-5-propylfuran-2-yl)decanoylcarnitine

3-{[10-(3,4-dimethyl-5-propylfuran-2-yl)decanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C26H45NO5 (451.32975600000003)


10-(3,4-dimethyl-5-propylfuran-2-yl)decanoylcarnitine is an acylcarnitine. More specifically, it is an 10-(3,4-dimethyl-5-propylfuran-2-yl)decanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 10-(3,4-dimethyl-5-propylfuran-2-yl)decanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 10-(3,4-dimethyl-5-propylfuran-2-yl)decanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

11-(5-ethyl-3,4-Dimethylfuran-2-yl)undecanoylcarnitine

3-{[11-(5-ethyl-3,4-dimethylfuran-2-yl)undecanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C26H45NO5 (451.32975600000003)


11-(5-ethyl-3,4-dimethylfuran-2-yl)undecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-(5-ethyl-3,4-dimethylfuran-2-yl)undecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-(5-ethyl-3,4-dimethylfuran-2-yl)undecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 11-(5-ethyl-3,4-dimethylfuran-2-yl)undecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-(5-Hexyl-3,4-dimethylfuran-2-yl)heptanoylcarnitine

3-{[7-(5-hexyl-3,4-dimethylfuran-2-yl)heptanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C26H45NO5 (451.32975600000003)


7-(5-hexyl-3,4-dimethylfuran-2-yl)heptanoylcarnitine is an acylcarnitine. More specifically, it is an 7-(5-hexyl-3,4-dimethylfuran-2-yl)heptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-(5-hexyl-3,4-dimethylfuran-2-yl)heptanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-(5-hexyl-3,4-dimethylfuran-2-yl)heptanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

8-(3,4-Dimethyl-5-pentylfuran-2-yl)octanoylcarnitine

3-{[8-(3,4-dimethyl-5-pentylfuran-2-yl)octanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C26H45NO5 (451.32975600000003)


8-(3,4-Dimethyl-5-pentylfuran-2-yl)octanoylcarnitine is an acylcarnitine. More specifically, it is an 8-(3,4-dimethyl-5-pentylfuran-2-yl)octanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-(3,4-Dimethyl-5-pentylfuran-2-yl)octanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 8-(3,4-Dimethyl-5-pentylfuran-2-yl)octanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

9-(5-Butyl-3,4-dimethylfuran-2-yl)nonanoylcarnitine

3-{[9-(5-butyl-3,4-dimethylfuran-2-yl)nonanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C26H45NO5 (451.32975600000003)


9-(5-Butyl-3,4-dimethylfuran-2-yl)nonanoylcarnitine is an acylcarnitine. More specifically, it is an 9-(5-butyl-3,4-dimethylfuran-2-yl)nonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-(5-Butyl-3,4-dimethylfuran-2-yl)nonanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 9-(5-Butyl-3,4-dimethylfuran-2-yl)nonanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

9-(3-Methyl-5-pentylfuran-2-yl)nonanoylcarnitine

3-{[9-(3-methyl-5-pentylfuran-2-yl)nonanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C26H45NO5 (451.32975600000003)


9-(3-Methyl-5-pentylfuran-2-yl)nonanoylcarnitine is an acylcarnitine. More specifically, it is an 9-(3-methyl-5-pentylfuran-2-yl)nonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-(3-Methyl-5-pentylfuran-2-yl)nonanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 9-(3-Methyl-5-pentylfuran-2-yl)nonanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Teleocidin B 2

17-ethenyl-6-(hydroxymethyl)-10,14,17-trimethyl-9,14-bis(propan-2-yl)-2,7,10-triazatetracyclo[9.7.1.0⁴,¹⁹.0¹³,¹⁸]nonadeca-1(18),3,11(19),12-tetraen-8-one

C28H41N3O2 (451.3198606)


   

Tomatidine HCl

(2aS,4S,5S,6aS,6bS,8aS,8bR,9S,10S,11aS,12aS,12bR)-5,6a,8a,9-tetramethyloctadecahydrospiro[naphtho[2,1:4,5]indeno[2,1-b]furan-10,2-piperidin]-4-ol hydrochloride

C27H45NO2.HCl (451.3216886)


Tomatidine hydrochloride acts as an anti-inflammatory agent by blocking NF-κB and JNK signaling[1]. Tomatidine hydrochloride activates autophagy either in mammal cells or C elegans[2]. Tomatidine hydrochloride acts as an anti-inflammatory agent by blocking NF-κB and JNK signaling[1]. Tomatidine hydrochloride activates autophagy either in mammal cells or C elegans[2].

   
   
   
   
   

Des-O-methylolivoretin C

Des-O-methylolivoretin C

C28H41N3O2 (451.3198606)


   

14-O-methylteleocidin A-1|5-O-Methylteleocidin A1

14-O-methylteleocidin A-1|5-O-Methylteleocidin A1

C28H41N3O2 (451.3198606)


   

ENY5VJU5UB

(2aS,4S,5S,6aS,6bS,8aS,8bR,9S,10S,11aS,12aS,12bR)-5,6a,8a,9-tetramethyloctadecahydrospiro[naphtho[2,1:4,5]indeno[2,1-b]furan-10,2-piperidin]-4-ol hydrochloride

C27H46ClNO2 (451.3216886)


Tomatidine hydrochloride acts as an anti-inflammatory agent by blocking NF-κB and JNK signaling[1]. Tomatidine hydrochloride activates autophagy either in mammal cells or C elegans[2]. Tomatidine hydrochloride acts as an anti-inflammatory agent by blocking NF-κB and JNK signaling[1]. Tomatidine hydrochloride activates autophagy either in mammal cells or C elegans[2].

   

CAR 20:2

(11Z,14Z)-icosadienoylcarnitine;11-cis,14-cis-eicosadienoylcarnitine;11-cis,14-cis-icosadienoylcarnitine;3-[(11Z,14Z)-icosa-11,14-dienoyloxy]-4-(trimethylammonio)butanoate

C27H49NO4 (451.36613940000007)


   
   

(7E,10S)-7-Henicosen-10-yl N-formyl-L-leucinate

(7E,10S)-7-Henicosen-10-yl N-formyl-L-leucinate

C28H53NO3 (451.40252280000004)


   

Tetrabutylammonium di-tert-butyl phosphate

Tetrabutylammonium di-tert-butyl phosphate

C24H54NO4P (451.37902540000005)


   

Teleocidin B4

Teleocidin B4

C28H41N3O2 (451.3198606)


D009676 - Noxae > D011042 - Poisons > D008235 - Lyngbya Toxins D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins D009676 - Noxae > D002273 - Carcinogens D009676 - Noxae > D007509 - Irritants

   

Teleocidin B-3

Teleocidin B-3

C28H41N3O2 (451.3198606)


D009676 - Noxae > D011042 - Poisons > D008235 - Lyngbya Toxins D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins D009676 - Noxae > D002273 - Carcinogens D009676 - Noxae > D007509 - Irritants

   

Teleocidin B-2

Teleocidin B-2

C28H41N3O2 (451.3198606)


D009676 - Noxae > D011042 - Poisons > D008235 - Lyngbya Toxins D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins D009676 - Noxae > D002273 - Carcinogens D009676 - Noxae > D007509 - Irritants

   

9-(3-Methyl-5-pentylfuran-2-yl)nonanoylcarnitine

9-(3-Methyl-5-pentylfuran-2-yl)nonanoylcarnitine

C26H45NO5 (451.32975600000003)


   

11-(3-Methyl-5-propylfuran-2-yl)undecanoylcarnitine

11-(3-Methyl-5-propylfuran-2-yl)undecanoylcarnitine

C26H45NO5 (451.32975600000003)


   

7-(5-Hexyl-3,4-dimethylfuran-2-yl)heptanoylcarnitine

7-(5-Hexyl-3,4-dimethylfuran-2-yl)heptanoylcarnitine

C26H45NO5 (451.32975600000003)


   

8-(3,4-Dimethyl-5-pentylfuran-2-yl)octanoylcarnitine

8-(3,4-Dimethyl-5-pentylfuran-2-yl)octanoylcarnitine

C26H45NO5 (451.32975600000003)


   

9-(5-Butyl-3,4-dimethylfuran-2-yl)nonanoylcarnitine

9-(5-Butyl-3,4-dimethylfuran-2-yl)nonanoylcarnitine

C26H45NO5 (451.32975600000003)


   

10-(3,4-Dimethyl-5-propylfuran-2-yl)decanoylcarnitine

10-(3,4-Dimethyl-5-propylfuran-2-yl)decanoylcarnitine

C26H45NO5 (451.32975600000003)


   

11-(5-ethyl-3,4-Dimethylfuran-2-yl)undecanoylcarnitine

11-(5-ethyl-3,4-Dimethylfuran-2-yl)undecanoylcarnitine

C26H45NO5 (451.32975600000003)


   

(8Z,11Z)-Icosa-8,11-dienoylcarnitine

(8Z,11Z)-Icosa-8,11-dienoylcarnitine

C27H49NO4 (451.36613940000007)


   
   

(2S,3R,4E)-2-azaniumyl-3-hydroxy-15-methylhexadec-4-en-1-yl 2-(trimethylazaniumyl)ethyl phosphate

(2S,3R,4E)-2-azaniumyl-3-hydroxy-15-methylhexadec-4-en-1-yl 2-(trimethylazaniumyl)ethyl phosphate

C22H48N2O5P+ (451.3300668)


   

2-[[(E,2S,3R)-2-amino-3-hydroxyheptadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(E,2S,3R)-2-amino-3-hydroxyheptadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C22H48N2O5P+ (451.3300668)


   

15-Methylhexadecasphing-4-enine-1-phosphocholine(1+)

15-Methylhexadecasphing-4-enine-1-phosphocholine(1+)

C22H48N2O5P+ (451.3300668)


   

(Z)-N-[(E)-1,3-dihydroxynon-4-en-2-yl]nonadec-9-enamide

(Z)-N-[(E)-1,3-dihydroxynon-4-en-2-yl]nonadec-9-enamide

C28H53NO3 (451.40252280000004)


   

N-[(4E,8E)-1,3-dihydroxydocosa-4,8-dien-2-yl]hexanamide

N-[(4E,8E)-1,3-dihydroxydocosa-4,8-dien-2-yl]hexanamide

C28H53NO3 (451.40252280000004)


   

(Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]icos-11-enamide

(Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]icos-11-enamide

C28H53NO3 (451.40252280000004)


   

(9Z,12Z)-N-(1,3-dihydroxynonan-2-yl)nonadeca-9,12-dienamide

(9Z,12Z)-N-(1,3-dihydroxynonan-2-yl)nonadeca-9,12-dienamide

C28H53NO3 (451.40252280000004)


   

(11Z,14Z)-N-(1,3-dihydroxyoctan-2-yl)icosa-11,14-dienamide

(11Z,14Z)-N-(1,3-dihydroxyoctan-2-yl)icosa-11,14-dienamide

C28H53NO3 (451.40252280000004)


   

N-[(4E,8E)-1,3-dihydroxypentacosa-4,8-dien-2-yl]propanamide

N-[(4E,8E)-1,3-dihydroxypentacosa-4,8-dien-2-yl]propanamide

C28H53NO3 (451.40252280000004)


   

N-[(4E,8E)-1,3-dihydroxyhenicosa-4,8-dien-2-yl]heptanamide

N-[(4E,8E)-1,3-dihydroxyhenicosa-4,8-dien-2-yl]heptanamide

C28H53NO3 (451.40252280000004)


   

N-[(4E,8E)-1,3-dihydroxyhexacosa-4,8-dien-2-yl]acetamide

N-[(4E,8E)-1,3-dihydroxyhexacosa-4,8-dien-2-yl]acetamide

C28H53NO3 (451.40252280000004)


   

N-[(4E,8E)-1,3-dihydroxyicosa-4,8-dien-2-yl]octanamide

N-[(4E,8E)-1,3-dihydroxyicosa-4,8-dien-2-yl]octanamide

C28H53NO3 (451.40252280000004)


   

N-[(4E,8E)-1,3-dihydroxynonadeca-4,8-dien-2-yl]nonanamide

N-[(4E,8E)-1,3-dihydroxynonadeca-4,8-dien-2-yl]nonanamide

C28H53NO3 (451.40252280000004)


   

N-[(4E,8E)-1,3-dihydroxytetracosa-4,8-dien-2-yl]butanamide

N-[(4E,8E)-1,3-dihydroxytetracosa-4,8-dien-2-yl]butanamide

C28H53NO3 (451.40252280000004)


   

N-[(4E,8E)-1,3-dihydroxytricosa-4,8-dien-2-yl]pentanamide

N-[(4E,8E)-1,3-dihydroxytricosa-4,8-dien-2-yl]pentanamide

C28H53NO3 (451.40252280000004)


   

(9Z,12Z)-N-(1,3-dihydroxydodecan-2-yl)hexadeca-9,12-dienamide

(9Z,12Z)-N-(1,3-dihydroxydodecan-2-yl)hexadeca-9,12-dienamide

C28H53NO3 (451.40252280000004)


   

N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]pentadecanamide

N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]pentadecanamide

C28H53NO3 (451.40252280000004)


   

(9Z,12Z)-N-(1,3-dihydroxyundecan-2-yl)heptadeca-9,12-dienamide

(9Z,12Z)-N-(1,3-dihydroxyundecan-2-yl)heptadeca-9,12-dienamide

C28H53NO3 (451.40252280000004)


   

(Z)-N-[(E)-1,3-dihydroxyundec-4-en-2-yl]heptadec-9-enamide

(Z)-N-[(E)-1,3-dihydroxyundec-4-en-2-yl]heptadec-9-enamide

C28H53NO3 (451.40252280000004)


   

(9Z,12Z)-N-(1,3-dihydroxydecan-2-yl)octadeca-9,12-dienamide

(9Z,12Z)-N-(1,3-dihydroxydecan-2-yl)octadeca-9,12-dienamide

C28H53NO3 (451.40252280000004)


   

(Z)-N-[(E)-1,3-dihydroxytridec-4-en-2-yl]pentadec-9-enamide

(Z)-N-[(E)-1,3-dihydroxytridec-4-en-2-yl]pentadec-9-enamide

C28H53NO3 (451.40252280000004)


   

N-[(4E,8E)-1,3-dihydroxyoctadeca-4,8-dien-2-yl]decanamide

N-[(4E,8E)-1,3-dihydroxyoctadeca-4,8-dien-2-yl]decanamide

C28H53NO3 (451.40252280000004)


   

(Z)-N-[(E)-1,3-dihydroxypentadec-4-en-2-yl]tridec-9-enamide

(Z)-N-[(E)-1,3-dihydroxypentadec-4-en-2-yl]tridec-9-enamide

C28H53NO3 (451.40252280000004)


   

N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]hexadecanamide

N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]hexadecanamide

C28H53NO3 (451.40252280000004)


   

N-[(4E,8E)-1,3-dihydroxyheptadeca-4,8-dien-2-yl]undecanamide

N-[(4E,8E)-1,3-dihydroxyheptadeca-4,8-dien-2-yl]undecanamide

C28H53NO3 (451.40252280000004)


   

(Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]octadec-9-enamide

(Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]octadec-9-enamide

C28H53NO3 (451.40252280000004)


   

(Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]hexadec-9-enamide

(Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]hexadec-9-enamide

C28H53NO3 (451.40252280000004)


   

(Z)-N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]tetradec-9-enamide

(Z)-N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]tetradec-9-enamide

C28H53NO3 (451.40252280000004)


   

N-[(4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]tridecanamide

N-[(4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]tridecanamide

C28H53NO3 (451.40252280000004)


   

(Z)-N-[(8E,12E)-1,3,4-trihydroxypentadeca-8,12-dien-2-yl]dodec-5-enamide

(Z)-N-[(8E,12E)-1,3,4-trihydroxypentadeca-8,12-dien-2-yl]dodec-5-enamide

C27H49NO4 (451.36613940000007)


   

N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]tetradecanamide

N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]tetradecanamide

C28H53NO3 (451.40252280000004)


   

(Z)-N-[(8E,12E)-1,3,4-trihydroxytetradeca-8,12-dien-2-yl]tridec-8-enamide

(Z)-N-[(8E,12E)-1,3,4-trihydroxytetradeca-8,12-dien-2-yl]tridec-8-enamide

C27H49NO4 (451.36613940000007)


   

N-[(4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]dodecanamide

N-[(4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]dodecanamide

C28H53NO3 (451.40252280000004)


   
   
   
   
   
   
   
   
   

(Z)-N-[(E)-1,3-dihydroxypentadec-4-en-2-yl]tridec-8-enamide

(Z)-N-[(E)-1,3-dihydroxypentadec-4-en-2-yl]tridec-8-enamide

C28H53NO3 (451.40252280000004)


   

(Z)-N-[(E)-1,3-dihydroxyhexadec-4-en-2-yl]dodec-5-enamide

(Z)-N-[(E)-1,3-dihydroxyhexadec-4-en-2-yl]dodec-5-enamide

C28H53NO3 (451.40252280000004)


   

N-[(2S,3R,4E,6E)-1,3-dihydroxypentadeca-4,6-dien-2-yl]tridecanamide

N-[(2S,3R,4E,6E)-1,3-dihydroxypentadeca-4,6-dien-2-yl]tridecanamide

C28H53NO3 (451.40252280000004)


   

N-[(2S,3R,4E,14E)-1,3-dihydroxyoctadeca-4,14-dien-2-yl]decanamide

N-[(2S,3R,4E,14E)-1,3-dihydroxyoctadeca-4,14-dien-2-yl]decanamide

C28H53NO3 (451.40252280000004)


   

N-[(2S,3R,4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]tridecanamide

N-[(2S,3R,4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]tridecanamide

C28H53NO3 (451.40252280000004)


   

N-[(2S,3R,4E,8E)-1,3-dihydroxyoctadeca-4,8-dien-2-yl]decanamide

N-[(2S,3R,4E,8E)-1,3-dihydroxyoctadeca-4,8-dien-2-yl]decanamide

C28H53NO3 (451.40252280000004)


   

N-[(2S,3R,4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]tetradecanamide

N-[(2S,3R,4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]tetradecanamide

C28H53NO3 (451.40252280000004)


   

N-[(2S,3R,4E,6E)-1,3-dihydroxytetradeca-4,6-dien-2-yl]tetradecanamide

N-[(2S,3R,4E,6E)-1,3-dihydroxytetradeca-4,6-dien-2-yl]tetradecanamide

C28H53NO3 (451.40252280000004)


   

N-[(2S,3R,4E,6E)-1,3-dihydroxyhexadeca-4,6-dien-2-yl]dodecanamide

N-[(2S,3R,4E,6E)-1,3-dihydroxyhexadeca-4,6-dien-2-yl]dodecanamide

C28H53NO3 (451.40252280000004)


   

N-[(2S,3R,4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]dodecanamide

N-[(2S,3R,4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]dodecanamide

C28H53NO3 (451.40252280000004)


   

Teleocidin B-1

Teleocidin B-1

C28H41N3O2 (451.3198606)


D009676 - Noxae > D011042 - Poisons > D008235 - Lyngbya Toxins D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins D009676 - Noxae > D002273 - Carcinogens D009676 - Noxae > D007509 - Irritants

   

(11Z,14Z)-eicosadienoylcarnitine

(11Z,14Z)-eicosadienoylcarnitine

C27H49NO4 (451.36613940000007)


An O-acylcarnitine having (11Z,14Z)-eicosadienoyl as the acyl substituent.

   

SPHP(23:0)

SPHP(d23:0)

C23H50NO5P (451.34264200000007)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   
   
   
   
   
   
   
   
   
   
   
   

1-{11-methyl-5-[(2-methyl-octahydro-1h-quinolizin-4-yl)methyl]-6,14-diazapentacyclo[7.6.2.0²,⁷.0²,¹³.0¹³,¹⁷]heptadec-6-en-14-yl}ethanone

1-{11-methyl-5-[(2-methyl-octahydro-1h-quinolizin-4-yl)methyl]-6,14-diazapentacyclo[7.6.2.0²,⁷.0²,¹³.0¹³,¹⁷]heptadec-6-en-14-yl}ethanone

C29H45N3O (451.356244)


   

(6s,9s,14s,17s)-17-ethenyl-6-(hydroxymethyl)-9,14-diisopropyl-10,14,17-trimethyl-2,7,10-triazatetracyclo[9.7.1.0⁴,¹⁹.0¹³,¹⁸]nonadeca-1(18),3,7,11(19),12-pentaen-8-ol

(6s,9s,14s,17s)-17-ethenyl-6-(hydroxymethyl)-9,14-diisopropyl-10,14,17-trimethyl-2,7,10-triazatetracyclo[9.7.1.0⁴,¹⁹.0¹³,¹⁸]nonadeca-1(18),3,7,11(19),12-pentaen-8-ol

C28H41N3O2 (451.3198606)


   

(6s,9s,14r,17r)-17-ethenyl-6-(hydroxymethyl)-9,14-diisopropyl-10,14,17-trimethyl-2,7,10-triazatetracyclo[9.7.1.0⁴,¹⁹.0¹³,¹⁸]nonadeca-1(18),3,7,11(19),12-pentaen-8-ol

(6s,9s,14r,17r)-17-ethenyl-6-(hydroxymethyl)-9,14-diisopropyl-10,14,17-trimethyl-2,7,10-triazatetracyclo[9.7.1.0⁴,¹⁹.0¹³,¹⁸]nonadeca-1(18),3,7,11(19),12-pentaen-8-ol

C28H41N3O2 (451.3198606)


   

n-[(7s,9as,11as)-1-[1-(dimethylamino)ethyl]-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthren-7-yl]pyridine-3-carboximidic acid

n-[(7s,9as,11as)-1-[1-(dimethylamino)ethyl]-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthren-7-yl]pyridine-3-carboximidic acid

C29H45N3O (451.356244)


   

5-(3,7-dimethylocta-1,6-dien-3-yl)-10-isopropyl-13-(methoxymethyl)-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

5-(3,7-dimethylocta-1,6-dien-3-yl)-10-isopropyl-13-(methoxymethyl)-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

C28H41N3O2 (451.3198606)


   

(6s,9s,14r,17s)-17-ethenyl-6-(hydroxymethyl)-9,14-diisopropyl-10,14,17-trimethyl-2,7,10-triazatetracyclo[9.7.1.0⁴,¹⁹.0¹³,¹⁸]nonadeca-1(18),3,7,11(19),12-pentaen-8-ol

(6s,9s,14r,17s)-17-ethenyl-6-(hydroxymethyl)-9,14-diisopropyl-10,14,17-trimethyl-2,7,10-triazatetracyclo[9.7.1.0⁴,¹⁹.0¹³,¹⁸]nonadeca-1(18),3,7,11(19),12-pentaen-8-ol

C28H41N3O2 (451.3198606)


   

1-[(1s,2r,5s,9s,11r,13r,17r)-5-{[(2s,4s,9ar)-2-methyl-octahydro-1h-quinolizin-4-yl]methyl}-11-methyl-6,14-diazapentacyclo[7.6.2.0²,⁷.0²,¹³.0¹³,¹⁷]heptadec-6-en-14-yl]ethanone

1-[(1s,2r,5s,9s,11r,13r,17r)-5-{[(2s,4s,9ar)-2-methyl-octahydro-1h-quinolizin-4-yl]methyl}-11-methyl-6,14-diazapentacyclo[7.6.2.0²,⁷.0²,¹³.0¹³,¹⁷]heptadec-6-en-14-yl]ethanone

C29H45N3O (451.356244)


   

(6s,9s,14s,17r)-17-ethenyl-6-(hydroxymethyl)-9,14-diisopropyl-10,14,17-trimethyl-2,7,10-triazatetracyclo[9.7.1.0⁴,¹⁹.0¹³,¹⁸]nonadeca-1(18),3,7,11(19),12-pentaen-8-ol

(6s,9s,14s,17r)-17-ethenyl-6-(hydroxymethyl)-9,14-diisopropyl-10,14,17-trimethyl-2,7,10-triazatetracyclo[9.7.1.0⁴,¹⁹.0¹³,¹⁸]nonadeca-1(18),3,7,11(19),12-pentaen-8-ol

C28H41N3O2 (451.3198606)


   

(1s,2s,4ar,4bs,6as,9r,10s,10as,12ar)-1-(2-cyanoethyl)-1,4a,4b,9,10-pentamethyl-2-(prop-1-en-2-yl)-2,3,4,5,6,7,8,9,10,10a,12,12a-dodecahydrochrysene-6a-carboxylic acid

(1s,2s,4ar,4bs,6as,9r,10s,10as,12ar)-1-(2-cyanoethyl)-1,4a,4b,9,10-pentamethyl-2-(prop-1-en-2-yl)-2,3,4,5,6,7,8,9,10,10a,12,12a-dodecahydrochrysene-6a-carboxylic acid

C30H45NO2 (451.345011)


   

n-[(1s,3as,3br,5as,7s,9as,9bs,11as)-1-[(1s)-1-(dimethylamino)ethyl]-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthren-7-yl]pyridine-3-carboximidic acid

n-[(1s,3as,3br,5as,7s,9as,9bs,11as)-1-[(1s)-1-(dimethylamino)ethyl]-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthren-7-yl]pyridine-3-carboximidic acid

C29H45N3O (451.356244)


   

(3z,5s,6z,14s,16z)-5-tert-butyl-14-(hydroxymethyl)-10-isopropyl-2,9-dimethyl-1,12,15-triazatetracyclo[16.2.1.0⁸,²⁰.0¹¹,¹⁹]henicosa-3,6,8(20),10,16,18-hexaen-12-ol

(3z,5s,6z,14s,16z)-5-tert-butyl-14-(hydroxymethyl)-10-isopropyl-2,9-dimethyl-1,12,15-triazatetracyclo[16.2.1.0⁸,²⁰.0¹¹,¹⁹]henicosa-3,6,8(20),10,16,18-hexaen-12-ol

C28H41N3O2 (451.3198606)


   

7-tert-butyl-16-(hydroxymethyl)-13-isopropyl-4,12-dimethyl-1,12,15-triazatetracyclo[16.2.1.0⁸,²⁰.0¹¹,¹⁹]henicosa-3,8(20),9,11(19),14,18(21)-hexaen-14-ol

7-tert-butyl-16-(hydroxymethyl)-13-isopropyl-4,12-dimethyl-1,12,15-triazatetracyclo[16.2.1.0⁸,²⁰.0¹¹,¹⁹]henicosa-3,8(20),9,11(19),14,18(21)-hexaen-14-ol

C28H41N3O2 (451.3198606)


   

(3z,7r,13s,16s)-7-tert-butyl-16-(hydroxymethyl)-13-isopropyl-4,12-dimethyl-1,12,15-triazatetracyclo[16.2.1.0⁸,²⁰.0¹¹,¹⁹]henicosa-3,8(20),9,11(19),14,18(21)-hexaen-14-ol

(3z,7r,13s,16s)-7-tert-butyl-16-(hydroxymethyl)-13-isopropyl-4,12-dimethyl-1,12,15-triazatetracyclo[16.2.1.0⁸,²⁰.0¹¹,¹⁹]henicosa-3,8(20),9,11(19),14,18(21)-hexaen-14-ol

C28H41N3O2 (451.3198606)


   

(10z,13z,16z,19z,22z)-1-[5-(hydroxymethyl)-1h-pyrrol-2-yl]pentacosa-10,13,16,19,22-pentaen-1-one

(10z,13z,16z,19z,22z)-1-[5-(hydroxymethyl)-1h-pyrrol-2-yl]pentacosa-10,13,16,19,22-pentaen-1-one

C30H45NO2 (451.345011)


   

(10s,13s)-5-[(3r)-3,7-dimethylocta-1,6-dien-3-yl]-10-isopropyl-13-(methoxymethyl)-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

(10s,13s)-5-[(3r)-3,7-dimethylocta-1,6-dien-3-yl]-10-isopropyl-13-(methoxymethyl)-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

C28H41N3O2 (451.3198606)